Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Lenalidomide + Rituximab Hyaluronidase + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Rituximab Hyaluronidase||Rituxan Hycela|Rituximab and Hyaluronidase Human|Rituximab/Hyaluronidase||CD20 Antibody 12||Rituximab Hyaluronidase consists of a preparation of the CD20 antibody Rituxan (rituximab) combined with hyaluronidase, which upon delivery leads to break down of tissue hyaluronan by the hyaluronidase component, resulting in increased rituximab absorption and potentially resulting in enhanced complement-dependent and antibody-dependent cytotoxicity against CD20-positive tumor cells (NCI Drug Dictionary).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119||BCL2 inhibitor 20||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04447716||Phase I||Lenalidomide + Rituximab Hyaluronidase + Venetoclax Lenalidomide + Rituximab + Venetoclax||An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment||Recruiting||USA||0|